Barbara Burtness MD

Clinical Research Program Leader, Head and Neck Cancers Program; Co-Director, Developmental Therapeutics Research Program; Professor of Medicine (Medical Oncology)

Departments & Organizations

Office of Student ResearchCancer Center, Yale: Head and Neck Cancer Surgery Program; Developmental Therapeutics

Research Interests

EGFR expressed head and neck cancers. more...


  • AB, Bryn Mawr College, 05/1982
  • M.D., SUNY at Stonybrook, 1986

Selected Publications

  • Burtness B. Targeted agents: management of dermatologic toxicities. J Natl Compr Canc Netw. 2014 May;12(5 Suppl):793-6.PMID: 24853219
  • Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013 Jul;14(8):e302-9. doi: 10.1016/S1470-2045(13)70085-8. Review. PMID: 23816296
  • Mehra R, Zhu F, Yang DH, Cai KQ, Weaver J, Singh MK, Nikonova AS, Golemis EA, Flieder DB, Cooper HS, Lango M, Ridge JA, Burtness B. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers. Clin Cancer Res. 2013 Dec 1;19(23):6633-43. doi: 10.1158/1078-0432.CCR-13-0152. Epub 2013 Oct 2. PMID: 24088734



Latest News


Edit Profile